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The pineal hormone melatonin is involved in physiological
transduction of temporal information from the light dark
cycle to circadian and seasonal behavioural rhythms, as well
as possessing neuroprotective properties. Melatonin and its
receptors MT1 and MT2, which belong to the family of G pro-
tein-coupled receptors, are impaired in Alzheimer’s disease
(AD) with severe consequences to neuropathology and clin-
ical symptoms. The present data provides the first immuno-
histochemical evidence for the cellular localization of the
both melatonin receptors in the human pineal gland and
occipital cortex, and demonstrates their alterations in AD.We
localized MT1 and MT2 in the pineal gland and occipital cor-
tex of 7 elderly controls and 11 AD patients using immuno-
histochemistry with peroxidase-staining. In the pineal gland
both MT1 and MT2 were localized to pinealocytes, whereas in
the cortex both receptors were expressed in some pyramidal
and non-pyramidal cells. In patients with AD, parallel to
degenerative tissue changes, there was an overall decrease
in the intensity of receptors in both brain regions. In line with
our previous findings, melatonin receptor expression in AD is
impaired in two additional brain areas, and may contribute
to disease pathology.
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The pineal hormone melatonin, secreted in adiurnal pattern during darkness, provides acircadian and seasonal signal to the organism
in vertebrates (Reiter 1993; Savaskan 2002). Light
signals to the retina are transduced via the retino-
hypothalamic pathway to the suprachiasmatic
nucleus (SCN) of the hypothalamus which drives
the synthesis of melatonin in the pineal gland as a
hormonal message encoding the duration of dark-
ness (Stehle et al., 2003). Apart from the pineal
gland, melatonin is synthesized as well in the retina,
gut and Harderian gland, and its synthesis in these
organs also shows a daily rhythm.The pineal gland
seems to be the main source of melatonin con-
tributing to peripheral plasma melatonin levels
(Vanecek 1998). Besides its seasonal and circadian
regulatory functions, melatonin is involved in a vari-
ety of physiological responses including vasoactive,
visual, oncostatic and neuroimmunological proper-
ties (Reiter et al., 2003, 2001; Reiter 1991;
Savaskan 2002), and has high antioxidative and
neuroprotective effects (Pappolla et al., 2000;
Reiter et al., 2003, 2001).
Melatonin acts through specific plasma mem-
brane receptors (Ekmekcioglu 2006). To date, two
G-protein coupled melatonin membrane receptors,
MT1 and MT2, have been cloned in mammals, and
the newly purified MT3 protein belongs to the fami-
ly of quinone reductases (Ekmekcioglu 2006;
Nosjean et al., 2000).Whereas little is known about
the MT3-mediated effects of melatonin, MT1 and
MT2 are involved in different physiological effects
and in the antinoceptive, anxiolytic, antineophobic,
and locomotor activity modulatory effects of mela-
tonin (Uz et al., 2005). In addition to rodent tis-
sues, where the expression patterns of both recep-
tors have been well studied, some studies have
addressed melatonin receptor expression in human
CNS and found mRNA for both receptors in the
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cerebellum, hippocampus, cortex, thalamus and
retina (Al-Ghoul et al., 1998; Mazzucchelli et al.,
1999; Reppert et al., 1995). Using immunohisto-
chemistry, we have previously shown the cellular
localisation of MT1 and MT2 in the human hip-
pocampus, retina and in cerebrovascular tissues
(Savaskan et al., 2005, 2002a, b, 2001). The
expression patterns of both receptors were found to
be differentially altered in patients with
Alzheimer’s disease (AD), a progressively disabling
neurodegenerative disorder that is the major cause
of dementia in the elderly population. Nocturnal
melatonin levels are selectively decreased in AD
patients and AD-related sleep-wake cycle distur-
bances are associated with melatonin secretion
rhythm disorders (Pappolla et al., 2000; Swaab
2003;Wu & Swaab 2005).
Although the distribution of melatonin receptors
have been well studied in rodent brain, detailed
mapping of the receptors is still missing in humans.
Therefore the aim of the present study was to pro-
vide immunohistochemical evidence for the cellular
distribution of both melatonin receptors MT1 and
MT2 in the pineal gland and the occipital cortex of
elderly controls and AD patients. Since both brain
regions are heavily affected during the disease
pathology, the results may provide additional clues
for the involvement of melatonin system in aging
and neurodegeneration.
Materials and Methods
Human Tissue
Occipital cortex and pineal gland of 7 elderly con-
trol cases without neurological or psychiatric disor-
ders (4 female and 3 male; mean age: 69.7±4.9;
mean post-mortem delay: 390.3±23.7 minutes)
and 10 patients with AD (9 female and 1 male;
mean age: 79.8± 2.8; mean post-mortem delay:
355.70±45.56 minutes) were included in the study.
The demographic data of the cases is demonstrated
in Table 1. Heart failure or pneumonia was the
cause of death in all subjects. Paraffin-embedded
and paraformaldehyde-fixed tissue samples were
kindly provided by the Netherlands Brain Bank.
Sample collection was according to ethics commit-
tee criteria and the Declaration of Helsinki in
1975.The diagnosis of AD was performed accord-
ing to the NINCDS-ADRDA criteria (McKhann et
al., 1984) and confirmed by post-mortem neu-
ropathological examination. For the staging of the
various pathological hallmarks of AD the neu-
ropathological Braak staging (Braak&Braak
1991), and, as a major risk factor for sporadic AD,
apolipoprotein E (ApoE) allele frequency were
determined for each case. Braak stages 4-6 show
advanced neuropathological changes and corre-
spond to AD. The predominant ApoE alleles were
4/4 and 473 in AD cases, and 3/3 and 3/2 in con-
Table 1. Demographic and immunohistochemical data of elderly controls (C) and Alzheimer’s disease (AD) patients. Pmd: post-mortem
delay in minutes; BS: Braak staging (BS); ApoE: apolipoprotein E allele differentiation. NBB: Netherlands Brain Bank autopsy num-
bers. OC: Occipital cortex; PG: Pineal gland. F: female, M: male.
Case (NBB) Age Gender pmd BS ApoE OC: PG:
MT1 MT2 MT1 MT2
C: 1. 02-008 62 M 418 0 3/3 + ++ +++ +++
2. 03-033 61 F 410 0 3/2 +++ +++ +++ +++
3. 02-024 75 F 330 1 4/2 ++ ++ +++ ++
4. 02-087 71 M 460 1 3/3 +++ +++ +++ +++
5. 01-104 77 F 330 1 4/3 +++ +++ +++ +++
6. 03-006 91 F 320 3 3/2 +++ +++ +++ ++
7. 03-002 51 M 464 0 3/3 ++ ++ ++ ++
AD: 1. 01-095 81 F 330 6 4/4 + + ++ +
2. 02-002 92 M 210 4 3/3 - - ++ ++
3. 02-061 76 F 645 5 4/4 + + ++
4. 01-125 77 F 510 6 4/4 ++ ++ ++ ++
5. 02-021 64 F 220 6 4/3 ++ ++ ++ ++
6. 01-124 86 F 320 6 4/4 + ++ + +
7. 01-141 69 F 420 5 4/2 ++ ++ ++ ++
8. 02-047 83 F 427 5 4/3 + + + +
9. 02-085 79 F 255 5 3/3 + + ++ +
10. 01-129 91 F 220 6 3/3 + + ++ +
Staining intensities of the MT1 and MT2 immunoreactivities: (-): no immunopositive cellular structures; (+): slight, single immunopositive cellular structures; (++): moderate, at least
more than 5 immunopositive cellular structures on each section; (+++): high immunoreactivity, almost all cells are immunoreactive on each section (in OC in the layers II-V, in PG
pinealocytes).
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trol cases. Consecutive, coronal, 12 µm-thick, seri-
al tissue sections were used for the immunohisto-
chemical staining.Every tenth section in each series
was included in the study and at least ten sections
were used for the staining procedure.
Immunohistochemistry
The observed antigens, MT1 and MT2, were visu-
alized by peroxidase staining using the peroxidase
substrate 3-amino-9-ethylcarbazole. The staining
method has been previously reported in detail
(Savaskan et al., 2005, 2004, 2002a, b, 2001).The
experimentally determined optimum concentration
for the primary antibodies was 1:150 both for MT1
and MT2.The concentration of the secondary anti-
body was 1:100. The samples were counterstained
with Mayer’s hemalum. The experiments were per-
formed in duplicate. Adjacent sections to MT1- or
MT2-stained tissue samples were stained simultane-
ously to serve as control samples, using the same
procedure with the exception that primary antibod-
ies were omitted. All sections were assessed for
localization and intensity of specific immunoreac-
tivity on a semiquantitative scale of +/+++ by two
blind observers using a Zeiss Axiolab microscope.
Results
Pineal gland
The predominant cells of the pineal gland, the
pinealocytes, which produce
melatonin, were immunoreactive for both MT1
and MT2 (Figure 1 A, C, F). The pineal gland was
subdivided by the connective tissue septa into lob-
ules and pinealocytes. Cells with large, light and
round nuclei located within the lobules, displayed a
granular, perinuclear immunoreactivity for the two
antigens. MT1 and MT2 were located both in cell
somata and in cellular processes compactly filling
up the lobules. Immunoreactive cellular processes
framed the lobular border. All controls showed high
immunoreactivity for both receptors independent of
age, post-mortem delay, Braak staging or ApoE
allele type. In some sections acervuli cerebri or cal-
cium-containing concretions were found within the
pineal parenchyma which were free of immunore-
activity.
The immunoreactivities for MT1 and MT2 were
distinctly decreased in AD cases both in cell soma-
ta and cellular processes (Figure 1 B, D).Thus, the
pineal gland showed clear changes with reduced
number of pinealocytes within the lobules and a
reduced network of cellular processes displaying
slight immunoreactivity. The calcification was
increased in most AD cases. However, there was no
AD case missing MT1 or MT2 immunoreactivity.The
degree of the decrease in the immunoreactivities
did not correlate with age, post-mortem delay,
Braak staging or ApoE allele type.
Occipital cortex
Cells in the cortical layers II to V displayed MT1
and MT2 immunoreactivity (Figure 2 A, B, D).The
outermost of the six cortical layers (the molecular
layer or layer I), and the deepest layer (the multi-
form layer or layer VI), contained no MT1MT1 or
MT2 immunoreactive cells besides a few cells of the
second layer scattering into the layer I. Some
pyramidal-shaped and non-pyramidal cells of layers
II to V, on the other hand, showed a distinct granu-
lar, cytoplasmic and perinuclear immunoreactivity
for MT1 and MT2 (Figure 2 A, B, D). Interestingly,
not all pyramidal and non-pyramidal cells were
found to express the receptors and in some sections
MT1 and MT2 immunoreactive cells formed
descending cellular columns throughout several
layers (Figure 2 B, D). The layers of the occipital
cortex were not clearly subdivided, and pyramidal
and non-pyramidal cells were mixed within different
layers. Apical dendrites of the pyramidal neurons
and some cellular processes were also immunore-
active for both receptors.
Similar to the pineal gland, immunoreactivities
for MT1 and MT2 were decreased in the AD cases,
both in pyramidal and non-pyramidal cells (Figure
2 C, E). In general, less cells were stained for the
receptors in the AD cortex.The decreased intensity
of the MT1 or MT2 immunoreactivities did not cor-
relate with age, post-mortem delay, Braak staging
or ApoE allele type.
Discussion
The present data provides the first immunohisto-
chemical evidence for the
cellular localizations of the two melatonin recep-
tors MT1 and MT2 in the human pineal gland and
occipital cortex, and demonstrates decreased
expression of the receptors in AD.
The pinealocytes of the pineal gland are the pro-
duction site of melatonin and, as shown in the pres-
ent study, the main cells expressing both MT1 and
MT2.The rhythmic melatonin secretion in the pineal
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gland is controlled by the SCN innervating the
gland via the dorsomedial hypothalamic nucleus,
the upper thoracic intermediolateral cells columns
of the spinal cord and the superior cervical ganglia
(Wu&Swaab 2005). The sympathetic stimulus is
crucial for pineal melatonin secretion and a circa-
dian rhythm of β1-adrenergic receptors has been
found in human pinealocytes (Oxenkrug et al.,
1990). In turn, pineal melatonin elicits two distinct,
separable effects on the SCN through its receptors,
i.e. acute neuronal inhibition and phase shifting
(Liu et al., 1997). As shown in the present study
melatonin may also act locally via melatonin recep-
tors on pinealocytes.
The pineal gland shows age- and AD-related
changes which is reflected by continuously decreas-
ing melatonin levels (Wu&Swaab 2005). The
acervuli cerebri or calcium-containing concretions
in the pineal gland, which were commonly observed
in our series, increase with age, however, there is no
clear evidence that pineal calcification affects
pineal metabolism (Wu&Swaab 2005).Thus, in the
elderly, there are no obvious degenerative changes
in the pineal gland (Pardo et al., 1990). Similarly
in our control series, the pineal gland consisted of a
compact tissue of pinealocytes with no clear degen-
erative alterations. On the other hand, the opposite
was the case in the AD series: the pineal gland
showed a distinct decrease in pinealocytes and their
cellular processes indicating cell loss.We have also
observed more calcium concretions within the
gland.This is in contrast to previous findings report-
ing no alternation in calcium deposition in the
pineal gland in AD (Friedland et al., 1990), nor in
pineal weight or pineal total protein content (Wu et
al., 2003).Thus, the pineal cells and afferent fibers
were found to be clear of AD-related changes, i.e.
neurofibrillary tangles, the accumulation of neuro-
filaments, tau, hyperphosphorylated tau or amyloid
deposition (Pardo et al., 1990). However, loss of
melatonin rhythmicity has been found to occur
already in early AD neuropathology, possibly relat-
ed to the severe degenerative changes in the SCN
(Wu&Swaab 2005), and, in addition, to the dys-
function of pineal noradrenergic regulation and the
depletion of pineal serotonin by increased
Figure 1. MT1 and MT2 in the
pineal gland. (A) The cell somata
and cellular processes of the
pinealocytes are immunoreactive
for MT1 (red-brown deposits) in a
control case. (B) MT1 immunore-
active structures in an AD case.
The density of the immunoreac-
tivity and the cell count of the
cells are distinctly decreased
(star indicates calcification). (C)
MT2 immunoreactive pinealo-
cytes in a control case (star indi-
cates calcification). (D)
Decreased MT2 immunoreactivity
in an AD case. (E) Control sec-
tion stained simultaneously
according to the same procedure,
with the exception that the pri-
mary antibody (for MT1) was omit-
ted. (F) Lower magnification
micrograph of the pineal gland
demonstrating the lobular struc-
ture of the tissue, stained for
MT1. (A-E) Original magnification
x242. (F) Original magnification
x60.
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monoamine oxidase A activity (Wu et al., 2003).
The AD pineal glands in our series show obvious
degenerative changes which are clearly distinguish-
able from control cases. Moreover, MT1 and MT2
expression on pinealocytes are severely affected
suggesting that parallel to degenerative changes in
the pineal gland the melatonin receptor system may
be impaired during the disease course. The alter-
ations in receptor expression may be also a conse-
quence of altered melatonin, since changes in pineal
melatonin levels have been shown to autoregulate
the density of its receptors (Guerrero et al., 2000).
Melatonin binding in the cerebral cortex can be
detected very early in the human fetus (Yuan et al.,
1991) and several studies have demonstrated the
presence of MT1 mRNA in the human cortex,
including the occipital cortex (Mazzucchelli et al.,
1999; Uz et al., 2005). Compared to frontal and
temporal cortex the level of the MT1 messenger was
highest in the parietal and occipital cortex
(Mazzucchelli et al., 1999). In other mammalian
species, the relative abundance of mRNA in various
cortical regions was found to correspond well with
melatonin receptor density in the same areas
(Bittman&Weaver 1990; Stankov et al., 1992).
However, direct comparison with expression of the
receptor protein could not be performed because of
extremely low specific binding obtained in in vitro
ligand-binding experiments (Mazzucchelli et al.,
1999).The authors consider that this may suggest
low expression, or, alternatively, a limited number of
specialized neurons may express melatonin recep-
tors in the various cortical regions of the human
brain, implying discrete differences in function
(Mazzucchelli et al., 1999). Also in our series, not
all pyramidal and non-pyramidal cells in the occip-
ital cortex were positive for MT1 or MT2, and, in
some sections, melatonin receptor positive cells
were found to be organized in columns of a group
of cells. Together with previous findings, these
results may be indicative for localization of both
melatonin receptors in subgroups of cortical cells
with a specific function. Indeed, the presence of
MT1 proteins has been demonstrated in areas relat-
ed to dopaminergic behaviours including the pre-
frontal cortex (Uz et al., 2005).
Figure 2. MT1 and MT2 in the
occipital cortex. (A) MT1
immunoreactive pyramidal cell in
a control case. (B) MT2
immunoreactive non-pyramidal
cells in columnar organisation.
(C) Decreased MT1 immunoreac-
tivity in pyramidal and non-pyram-
idal cells in an AD case. (D)
Lower magnification micrograph
of the cortex with MT2 immunore-
active cells in columnar organisa-
tion. (E) Decreased MT2
immunoreactivity in pyramidal
and non-pyramidal cells in an AD
case. (F) Control section omit-
ting the primary antibody (for
MT1). (A-C, E, F) Original magnifi-
cation x242. (D) Original magnifi-
cation x60.
In the present study both MT1 and MT2 were
located on pyramidal and non-pyramidal cortical
cells.There is growing evidence that G protein-cou-
pled receptors such as MT1 and MT2 co-localized
on the same cell are organized as homo- and het-
erodimers and this oligomerization may have
important consequences for receptor function
(Levoye et al., 2006). The formation of MT1 and
MT2 homodimers and MT1/MT2 heterodimers
occurs at physiological expression levels and the
formation of MT1/MT2 heterodimers in native tis-
sues is suggested by the co-expression of MT1 and
MT2 in many melatonin-sensitive tissues (Levoye et
al., 2006). In line with this observation, our results
may indicate co-localization of the two melatonin
receptors in human cortical cells.
Both MT1 and MT2 were decreased in AD. We
have previously shown that both receptors are
impaired in the AD hippocampus (Savaskan et al.,
2005, 2002a), a region highly implicated in AD
pathology.Whereas MT2 was found to be decreased
in AD hippocampus, the expression of MT1 was
increased. Therefore, the AD-related alterations in
melatonin receptors may be region-specific, with an
overall loss of expression in the pineal gland and
occipital cortex. In conclusion, both G protein-cou-
pled melatonin receptors MT1 and MT2 are
expressed in the pineal gland and occipital cortex
on the same cellular structures, and the intensity of
both receptors decreases during AD pathology.
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